Use of Inhibitors of the Renin-Angiotensin System for the Treatment of Lung Injuries
AssigneeImba-Institute Fur Molekulare Biotechnologie GmbH
InventorsJosef Penninger, Yumiko Imai, Keiji Kuba, Chengyu Jiang
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of Angiotensin Converting enzyme 2 (ACE2) for the preparation of a medicament for the treatment of severe acute lung injury, especially induced by acid aspiration or sepsis, of lung oedemas and lung injuries and failures connected with infection with severe acute respiratory Syndrome (SARS) Coronavirus.
Claims29
-15. (canceled)
A method of treating a severe acute lung injury or failure in a subject comprising providing Angiotensin converting enzyme 2 (ACE2) to a subject with a severe acute lung injury or failure, wherein the severe acute lung injury or failure in the subject is treated.
A pharmaceutical composition comprising ACE2 and at least one of an inhibitor of the Renin-Angiotensin-System and a bradykinin receptor inhibitor.
A method of treating a severe acute lung injury or failure in a subject comprising providing an inhibitor of a Renin-Angiotensin-System to a subject with a severe acute lung injury or failure, wherein the severe acute lung injury or failure in the subject is treated.
A method of treating a severe acute lung injury or failure in a subject comprising providing bradykinin receptor inhibitor to a subject with a severe acute lung injury or failure, wherein the severe acute lung injury or failure in the subject is treated.
Dependencies are inferred from the claim text.